We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Outsourcing Drug Development Increasingly Global

By LabMedica International staff writers
Posted on 03 Nov 2008
Fueled by rising market pressures, companies are increasingly outsourcing the drug development process. More...
In the United States, not only the complexity of conducting clinical trials has grown over the last 20 years, but also the number of drugs in development increased, government regulations tightened, and patient recruitment became more difficult.

A new report from Kalorama Information (New York, NY, USA), an international market research company, revealed that in 2007 34% of global research and development spending, or US$26.4 billion, was committed to outsourcing, up from 22% in 2002, an increasing amount of which is going offshore.

Developing and bringing a drug to market costs over $900 million and takes as long as 15 years, whereas over 80% of drugs that enter clinical trials fail to be approved by the U.S. Food and Drug Administration (FDA). Now, in order to decrease research and development (R&D) expenses and accelerate drug discovery and development, developers are outsourcing more of their R&D functions. However, a key obstacle remains--the patient recruitment and retention process--particularly as clinical trial protocols become more complicated, delays can result in millions of dollars of lost sales.

In response, the outsourcing trend has begun to move offshore as drug developers seek patient recruitment in large populations of people eager to take part in clinical trial research, especially in Eastern Europe, Asia, and Latin America. These regions can often produce the required number of participants in half the time, with better compliance and less expensive medical professionals.

"Pharmaceutical marketing is truly global right now,” noted Kalorama Information's publisher Bruce Carlson. "Developers need to submit new drugs for approval in multiple countries simultaneously, rather than in succession, in order to maximize revenue and reduce costs. Recruiting volunteers in multiple countries is essential.”

Currently, however, the United States remains the world's largest clinical research market with just over half of all worldwide trial sites still located there.

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of research services.

Related Links:

Kalorama Information



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.